



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10057,596
Filing Date	01/24/2002
First Named Inventor	Douglas C. Shepard
Group Art Unit	1615
Examiner Name	Unassigned

Attorney Docket Number	01-531
------------------------	--------

RECEIVED
OCT 06 2003
TECH CENTER 1600/2900

Examiner Signature	<i>K. K. K.</i>	Date Considered	10/04
-----------------------	-----------------	--------------------	-------

EXAMINER: Initial if enforcement considered, whether or not citation is levied.

Unique citation designation number. ² See Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)
01-531

Application Number
Unassigned

Applicant(s)
Douglas C. Shepard

Filing Date
Filed Herewith

Group Art Unit
Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LSA	1	4,525,456	6/25/85	Rohrbach	435	176	
	2	6,024,918	2/15/00	Hendriks et al.	422	44	
	3	6,033,719	3/7/00	Keogh	422	2.12	
LSA	4	6,077,714	6/20/00	Spallholz et al.	436	525	

10/05/98
10/24/02
10/05/98
10/24/02

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LSA	1	Senatore et al., "Fibrinolytic activity of immobilized plasminogen activator," Res Commun Chem Pathol Pharmacol 1985 Aug;49(2) 295-304, Abstract only.
LSA	2	Forster et al., "Analysis of urokinase immobilization on the polytetrafluoroethylene vascular prosthesis," Am J Surg 1988: 156(2): 130-2, Abstract only

EXAMINER

Kush

DATE CONSIDERED

10/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

01-531

Application Number

Unassigned

Applicant(s)

Douglas C. Shepard

Filing Date

Filed Herewith

Group Art Unit

Unassigned

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

3

Harvey et al., "Binding of tissue plasminogen activator to vascular grafts," Thromb Haemost 1989 Feb;61(1):131-6, Abstract Only

4

Jefferies et al., "Preliminary studies with L-asparaginases bound to implantable bovine collagen heterografts: a potential long-term, sustained dosage, antitumor enzyme therapy system," Biomater Med Devices Artif Organs 1977;5(4):3337-54, Abstract Only.

5

Raghavan et al., "Degradation of oxalate in rats implanted with immobilized oxalate oxidase," FEBS Lett 1986 Jan 20;195(1-2):101-5, Abstract Only.

6

Jamie Y. Jeremy et al., "Nitric oxide and the proliferation of vascular smooth muscle cells," Cardiovascular Research 1999 Aug 15;43(3):580-94.

EXAMINER

Koshe

DATE CONSIDERED

10/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.